Screener
Jade Biosciences JBIO Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Series Seed Convertible Preferred Stock / Shares | Series Seed Convertible Preferred Stock / Amount | Series A Convertible Preferred Stock / Shares | Series A Convertible Preferred Stock / Amount | Common Stock / Shares | Common Stock / Amount | Additional Paid-In / Capital | Accumulated Other Comprehensive / (Loss) Income | Accumulated / Deficit | Total Stockholders’ / Equity (Deficit) |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance at December 31, 2024 | 20,000,000 | $2 | — | — | 3,672,794 | $1 | $179 | — | $(46,979) | $(46,799) |
| Stock-based compensation | — | — | — | — | — | — | 1,458 | — | — | 1,458 |
| Net loss | — | — | — | — | — | — | — | — | (38,169) | (38,169) |
| Balance at March 31, 2025 | 20,000,000 | $2 | — | — | 3,672,794 | $1 | $1,637 | — | $(85,148) | $(83,510) |
| Series SeedConvertible Preferred Stock | Series A Convertible Preferred Stock | Common Stock | AdditionalPaid-In | Accumulated Other Comprehensive | Accumulated | TotalStockholders’ | ||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | (Loss) Income | Deficit | Equity | |
| Balance at December 31, 2025 | — | — | 12,622 | 2 | 49,316,287 | $5 | $506,771 | $129 | $(174,389) | $332,518 |
| Exercise of stock options | — | — | — | — | 29,680 | — | 45 | — | — | 45 |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's net income?
- Jade Biosciences (JBIO) reported net income of -$40.37M in Q1 2026.
- How has Jade Biosciences's net income changed year-over-year?
- Jade Biosciences's net income decreased by 5.8% year-over-year, from -$38.17M to -$40.37M.
- What is the long-term trend for Jade Biosciences's net income?
- Over 4 years (2021 to 2025), Jade Biosciences's net income has grown at a 53.5% compound annual growth rate (CAGR), from -$22.96M to -$127.41M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Jade Biosciences's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude